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Decreased maternal serum acetate and impaired
fetal thymic and regulatory T cell development in
preeclampsia
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Maternal immune dysregulation seems to affect fetal or postnatal immune development.
Preeclampsia is a pregnancy-associated disorder with an immune basis and is linked to atopic
disorders in offspring. Here we show reduction of fetal thymic size, altered thymic archi-
tecture and reduced fetal thymic regulatory T (Treg) cell output in preeclamptic pregnancies,
which persists up to 4 years of age in human offspring. In germ-free mice, fetal thymic CD4+
T cell and Treg cell development are compromised, but rescued by maternal supplementation
with the intestinal bacterial metabolite short chain fatty acid (SCFA) acetate, which induces
upregulation of the autoimmune regulator (AIRE), known to contribute to Treg cell genera-
tion. In our human cohorts, low maternal serum acetate is associated with subsequent
preeclampsia, and correlates with serum acetate in the fetus. These findings suggest a
potential role of acetate in the pathogenesis of preeclampsia and immune development in
offspring.
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The maternal and early in utero environment probablyaffects health and disease later in life. This is particularlytrue of non-communicable diseases such as allergy and
autoimmunity1. Preeclampsia is a common pregnancy-associated
disorder that is unique to humans. It is believed to develop due to
a breakdown in maternal-fetal immune tolerance, as demon-
strated by maternal immune alterations including reduced reg-
ulatory T (Treg) cells2,3. Maternal immune changes in
preeclampsia are generally mirrored in the fetal immune system4.
In turn, there is some evidence that preeclampsia is associated
with higher rates of allergy5,6 and cardiovascular disease7–9 in
offspring. This is suggestive of a common, environmental or
physiological factor that influences both maternal and fetal
immune systems.
Short chain fatty acids (SCFAs), mainly acetate, butyrate and
propionate, are major metabolic products of the gut microbiota,
mostly produced through bacterial fermentation of dietary fiber.
SCFAs have potent anti-inflammatory effects, which probably
relate to their role in the gut and systemic immune
homeostasis10,11. Butyrate is mainly (70–90%) absorbed by the
colonic epithelium, whereas propionate is mostly taken up by
the liver12, leaving acetate as the most prominent circulating
SCFA. Serum acetate concentrations range from 70–170 μM12–14,
in contrast to propionate and butyrate with serum concentrations
ranging from 1–13 μM12. Three recent murine studies also
showed that dietary acetate and butyrate can protect against the
development of food allergy, asthma, and autoimmune type 1
diabetes (T1D) through modulation of immune tolerance15,16.
For example, acetate and butyrate from high-fiber diet increased
Treg numbers through enhancing retinol dehydrogenase activity
in CD103+ tolerogenic dendritic cells (DCs)13 or directly via
HDAC inhibition14. Maternal intake of dietary fiber/acetate
during pregnancy protected offspring from allergic airways dis-
ease (AAD) correlated with markedly increased Treg function15.
Young non-obese diabetic (NOD) mice, treated with a combi-
nation of modified starches that release microbial acetate and
butyrate, were protected from developing autoimmune type 1
diabetes (T1D) in 90% of cases, resulting from the cessation of β-
cell destruction and restored immune tolerance associated with
expanded Treg cells, and reduced autoreactive CD4+ and CD8+
T cells16. In addition, dietary acetate has been found also to
protect against cardiovascular disease and hypertension in mouse
models15,16.
Interestingly, there is some evidence suggesting maternal gut
microbiota may influence the pathogenesis of preeclampsia, with
probiotic use associated with a reduced risk of preeclampsia17.
Additionally, a Mediterranean diet as well as a diet high in fiber,
which promote SCFA production, are also associated with
decreased preeclampsia18,19. Furthermore, in a murine model,
supplementation of high fiber or direct supplementation of
acetate significantly reduced both systolic and diastolic blood
pressures, a finding highly relevant to preeclampsia with hyper-
tension as a defining clinical feature20.
Maternal microbial ecology is known to influence fetal immune
development21. In mice, several studies have shown that maternal
microbial composition is important for the protection against the
development of allergic disease in the offspring22,23 and can
influence the infant immune response24. In humans, various
cross-sectional and cohort studies have confirmed these findings
and shown that maternal microbial exposure (for example in the
farm environment) is associated with changes in offspring
immune profiles and protection against atopic disorders25,26.
Exactly how this protection is conferred is unknown; however, a
role for Treg cells27 and Toll ligand receptors (TLR), which can be
activated by bacterial products27, has been inferred. Therefore, an
alluring concept is that levels of production of SCFAs by maternal
gut microbiota may influence both maternal and fetal immune
homeostasis during pregnancy.
In this study, we present evidence of an association between
maternal gut microbial metabolites and fetal immune develop-
ment in preeclampsia. Specifically, we demonstrate in mice a link
between acetate and fetal thymic development and output, with
concordant associations in human cohorts between decreased
serum acetate and subsequent preeclampsia, and between pre-
eclampsia and decreased thymic size and output in the offspring.
Maternal acetate supplementation had a significant impact on the
fetal immune system in a germ-free mouse model, with offspring
demonstrating increased CD4+ T-cell production, improved
Foxp3 expression and rescue of specialized thymic epithelial cells
expressing the AIRE gene, essential for self-tolerance induction
and Treg cell generation early in life28.
Results
Fetal thymic development is compromised in preeclamptic
pregnancies. We have shown previously that reduced fetal thymic
size is evident in preeclamptic pregnancies by examining fetal
ultrasound images in retrospectively assembled case–control
series29. Here, we performed prospective studies in two separate
cohorts. First, we compared fetal thymus volume and diameter
measurements between 50 preeclamptic and 50 non-preeclamptic
pregnant women (Nepean cohort 1, patient characteristics are
shown in Supplementary Table 1a). Then in a second cohort, we
recruited 887 pregnant women between 17- and 22-week gesta-
tion, of whom 24 developed preeclampsia later in their preg-
nancies (Nepean cohort 2, patient characteristics are shown in
Supplementary Table 2).
Maternal and fetal characteristics in Nepean cohort 1 were
similar between the groups, except preeclampsia was associated
with increased rate of nulliparity, higher maternal body mass
index (BMI; measured at the first antenatal visit), a greater
average estimated fetal weight and earlier gestation at delivery
(Supplementary Table 1a). Antenatal ultrasound scans showed
that, compared to normal pregnancy, preeclampsia was associated
with a 38% decrease in fetal thymic volume (1.6 versus 2.6 mL,
p < 0.001 (unpaired t-test), Supplementary Table 1b) and 12.1%
decrease in fetal thymic diameter (2.9 versus 3.3 cm, p= 0.01
(unpaired t-test), Supplementary Table 1b). Evidence of differ-
ence persisted following adjustment for estimated fetal weight
percentile, maternal BMI, and smoking status (p= 0.04 and p=
0.009 for mean fetal thymus volume and diameter (univariate
logistic regression), respectively). The differences in thymus
volumes between preeclampsia and healthy controls were small at
early gestation but increased linearly over gestation (Fig. 1b). By
term, the average thymus volume in fetuses born to preeclampsia
women was approximately half of that in fetuses born to normal
pregnancies. For each 1 mL increase in volume, the mean thymus
diameter (MTD) increased on average by 1.03 cm (95% CI:
0.79–1.28, p < 0.001 (univariate logistic regression), R2= 41%).
In Nepean cohort 2, each pregnancy had fetal thymic
measurements performed at mid-gestation between 18 and
22 weeks, long before the onset of clinical preeclampsia. Once
again, preeclampsia was associated with smaller fetal thymus
diameter (Fig. 1d); adjusted means were 16.5 versus 18.3 mm,
respectively (p < 0.001 (unpaired t-test), Supplementary Table 2).
The odds of preeclampsia increased by 1.41 (1.17, 1.69) for each
1 mm decrease in fetal thymus diameter (p < 0.001, univariate
logistic regression). Adjusting for gestational age and maternal
BMI, multivariate logistic regression (Model 1) found the odds of
preeclampsia increased by 1.47 (1.22, 1.78) for each 1 mm
decrease in fetal thymus diameter (p < 0.001, univariate logistic
regression). The magnitude and evidence of association also
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persisted following adjustment for fetal head circumference and
maternal BMI (fetal thymus diameter odds ratio= 1.51 (1.23,
1.85, p < 0.001, univariate logistic regression).
Receiver operating characteristic (ROC) curves were generated
to evaluate fetal thymus diameter at mid-gestation as a predictive
tool for preeclampsia. Fetal thymus diameter at mid-gestation
alone was found to have an area under the curve (AUC) of 0.71.
Together with gestational age and maternal BMI, AUC increased
to 0.78. Since our group had previously found that increased fetal
head growth was also associated with preeclampsia after adjusting
cofounders30, we then included the fetal head circumference in
the model. When fetal thymus diameter at mid-gestation, fetal
head circumference at mid-gestation, gestational age, and
maternal BMI were included, we could reach an AUC of 0.81
(Supplementary Fig. 1).
Fetal thymic Treg cell output is reduced in preeclampsia. We
showed previously that cord blood and maternal blood Treg cell
percentages were highly correlated4, suggesting a common
mechanism for Treg control in both mother and fetus. Here, we
extended this finding and showed a correlation between maternal
and fetal Treg cell proportions in both healthy pregnancy and
preeclampsia. Patient characteristics (Nepean cohort 3) are shown
in Supplementary Table 3. Peripheral maternal Treg correlated
with cord blood Treg, but to a lesser extent in preeclampsia
compared to non-preeclamptic pregnancies and overall Treg
frequency was lower in preeclamptic dyads compared to non-
preeclamptics (Y intercept at X= 0: 2.68 ± 0.56 versus 2.51 ± 0.92,
p= 0.019, unpaired t-test) (Fig. 2a).
Maternal blood Tregs (the percentage of Foxp3+ cells within
CD4+ cells) were lower in preeclampsia (p= 0.004, unpaired t-
test) and similarly, there were some evidence of cord blood Treg
cell frequencies being lower in offspring of preeclamptic versus
non-preeclamptic pregnancies (p= 0.09, unpaired t-test) (Fig. 2b).
A subgroup of Nepean cohort 3 that included 21 non-preeclamptic
and 19 preeclamptic samples was selected based on access
to stored samples, and we performed further phenotypic
Treg cell analysis. We found that frequencies of cord blood
CD4+Foxp3+Helios+ thymic-derived natural Tregs (nTreg) were
also significantly lower in preeclampsia (p= 0.035, unpaired
t-test), especially in those who did not receive steroid treatment
(p= 0.01, one-way ANOVA with Dunnett’s multiple comparisons
test) (Fig. 2d). Altogether these findings show that offspring of
preeclamptic mothers have reduced thymic volume and diameter
with an associated deficit in the output of thymic Treg.
Reduced number of naive Treg cells persist into early child-
hood. To further examine whether the cord blood changes in
preeclampsia were persistent, we examined the CD4+CD45RA+
Foxp3+ thymic-derived naive Treg cells at birth, 6 and 12 months
and 4 years of age from the BIS cohort, an Australian birth cohort
study (n= 1064 mothers/1074 infants31, patient characteristics
are shown in Supplementary Table 4). There was some evidence
that the proportion of naive Treg cells in cord blood was lower
in infants born to mothers with preeclampsia (p= 0.057,
linear regression) (Fig. 3b), and this association was stronger
following adjustment for exposure to mode of delivery and gen-
der (p= 0.025, linear regression), factors that have been shown to
influence the proportion of cord blood naive Treg cells32. Long-
itudinal analysis revealed a persistent deficit in naive Treg pro-
portion in offspring of preeclamptic mothers over the first 4 years
of postnatal life (p= 0.004, generalized estimating equation)
(Fig. 3b).
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Fig. 1 Impaired fetal thymic development in preeclampsia. a Nepean cohort 1: Virtual organ computer-aided analysis calculation of the fetal thymus volume
at 26 weeks of gestation, showing three orthogonal planes (left top: transverse, right top: coronal, left down: sagittal) and reconstructed thymus volume
(right down). b Dot plot showing fetal thymus volumes in different gestational weeks in both non-preeclamptic (n= 50, black dots) and preeclamptic
(n= 50, red dots) groups. Mean ± SD: 2.6 ± 1.3 mL and 1.6 ± 1.2 mL, respectively (p < 0.001, unpaired t-test). c Nepean cohort 2: Fetal thymus diameter
measurement: an axial view of the fetal thymus was obtained, within a standard image of the right ventricular outflow tract (RVOT). Then a line was drawn
connecting the fetal spine and sternum (I). Fetal thymus diameter was measured as its greatest diameter (II), perpendicular to line I. Sp= spine,
S= superior vena cava, A= aorta, P= pulmonary artery. Scale bar= 5mm. d Dot plot showing fetal thymus diameter in different gestational weeks in both
non-preeclamptic (n= 863, black dots) and preeclamptic (n= 24, red dots) groups, adjusted means were 18.3 mm and 16.5 mm, respectively (p < 0.001,
unpaired t-test)
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Reduced thymic cortex and T-cell numbers on autopsy in
preeclampsia. Thymuses of preeclamptic cases from the Fetal
autopsy cohort (patient characteristics are shown in Supple-
mentary Table 5a), showed features of grade 2–3 thymic invo-
lution with loss of the normal distinction between cortex and
medulla observed at low magnification owing to advanced lym-
phophagocytosis and resulting in an irregular narrowing of the
cortex, foci of lymphodepletion and increased separation of
thymic lobules (Fig. 4). These are features commonly seen in
association with chronic intrauterine hypoxia that is seen in
preeclampsia33. Moreover, for the preeclampsia group, no
staining of Foxp3 was observed in these tissues. Conversely, in
both thymus and spleen, 4 out of 6 non-preeclamptic group
fetuses demonstrated Foxp3+ staining in <15% of cells. In the
thymuses of fetuses born to non-preeclamptic mothers, Foxp3+
expression was mainly limited to the medulla.
In all fetuses of non-preeclamptic cases, thymic CD4+ T cells
were predominant in the cortex, versus the medulla. However, in
4 out of 5 fetuses of preeclamptic cases, CD4+ T cells were equally
prevalent in thymic cortex and medulla. Within the spleen, CD4+
T-cell expression was reduced in fetuses of preeclamptic versus
non-preeclamptic mothers (Supplementary Table 5b). Taken
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Fig. 2 Reduced number of fetal Treg cells and fetal Treg thymic output in preeclampsia. Nepean cohort 3: a Scatter dot plot showing Treg cell frequencies in
term maternal-fetal dyads in both non-preeclamptic (non-PE) (n= 62, black dots) and preeclamptic (PE) pregnancies (n= 26, red dots). Pearson’s
correlation was used. Coefficient r and p-values as indicated. b Scattered dot plots comparing the %Foxp3+ (Mean) within CD4+ cells in cord blood (n=
66 for non-PE, n= 29 for PE group) and maternal blood (n= 62 for non-PE group, n= 27 for PE group) (unpaired t-test). Gating strategy for Foxp3+ Tregs
from PBMC is shown in Supplementary Fig. 2. c Representative dot plot showing cord blood Foxp3+Helios+ cells gated on CD4+ cells. d Scattered dot
plots showing the percentage of Foxp3+Helios+ cells (Mean) in cord blood. Left panel comparing %Foxp3+Helios+ cells in non-PE (n= 20) and PE (n=
19) groups (unpaired t-test). Right panel dividing the PE group into two subgroups based on steroids treatment: n= 10 for no Steroids and n= 9 for plus
Steroids (one-way ANOVA with Dunnett’s multiple comparisons test). *p < 0.05, **p < 0.01
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Fig. 3 Naive Treg cell changes in infants exposed to preeclampsia. BIS study: a Representative dot plot showing the gating strategy for naive Tregs gated on
CD4+ cells. b The line graphs showing the longitudinal naive Treg cell proportions (Mean ± SD, as a percentage of the CD4+ population) in children from
preeclamptic mothers (Red: at birth n= 11; 6-month n= 19; 1-year-old n= 22; 4-year-old n= 10) and children from non-hypertensive mothers (Black: at
birth n= 434; 6-month n= 558; 1-year-old n= 629; 4-year-old n= 377). The overall difference is –0.49% (95% CI –0.83, –0.16) (p= 0.004, generalized
estimating equation)
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together the above findings consistently demonstrate that
preeclampsia is associated with thymic involution and reduced
Treg expansion in offspring.
Serum acetate in healthy pregnancy and preeclampsia. Given
the evidence of the association between gut microbiota and pre-
eclampsia17–19, we then examined the metabolites of gut micro-
biota—SCFAs—in maternal serum at 28 weeks gestation and its
relationship with subsequent preeclampsia in the BIS cohort.
Consistent with previous findings, serum acetate levels were at
least tenfold higher compared to butyrate and propionate (Fig. 5a).
On weighted logarithmic regression analysis, there was also evi-
dence of associations between lower serum SCFAs and subsequent
preeclampsia (Fig. 5b–d). The relative risk of developing pre-
eclampsia was decreased per 30% increase in the serum acetate
(RR 0.77, 95% CI 0.61–0.96, p= 0.021, weighted logarithmic
regression). This evidence persisted following adjustment for
maternal age (p= 0.031, weighted logarithmic regression). In a
smaller subset in which pre-pregnancy BMI had been recorded (24
with preeclampsia, 253 without), the evidence of an association
between serum acetate and preeclampsia was weak (p= 0.178,
logarithmic regression) but minimally changed by adjustment for
pre-pregnancy BMI (p= 0.143, logarithmic regression). Pre-
pregnancy BMI was associated with preeclampsia (p= 0.003,
logarithmic regression) but there was no evidence that this asso-
ciation was mediated by serum acetate (proportion of total effect
mediated –3%, 95% CI –55 to 20%). The evidence of a univariate
association between serum acetate and preeclampsia was also
attenuated by the exclusion of one older mother with low serum
acetate and postnatal preeclampsia (RR 0.46, 95% CI 0.20–1.06,
p= 0.067, logarithmic regression). In summary, an inverse asso-
ciation between lower serum acetate and subsequent preeclampsia
was observed in the overall cohort with and without adjustment
for maternal age but in a smaller subset, where pre-pregnancy
BMI values were available this association did not reach sig-
nificance. There was no evidence that maternal serum acetate
measured at 28 weeks gestation, was positively associated with
cord blood naive Treg. In the Nepean cohort 4 of paired maternal
and fetal serum (patient characteristics are shown in Supple-
mentary Table 6), collected no longer than 4 h apart, we did find a
correlation (r= 0.367, p= 0.012, Pearson’s correlation) between
cord blood and maternal blood acetate levels (Fig. 5e). This sug-
gests that maternal acetate may cross the placenta and therefore
influence fetal acetate levels. This is supported by our previous
work, which showed that in mice acetate does indeed cross the
placenta and affect concentrations in the developing fetus14.
Maternal acetate rescues fetal thymus in germ-free mice.
Mounting evidence suggests that SCFAs and other bacterial
metabolites influence T cell/Treg cell development14,34–37.
Therefore, we investigated whether maternal bacterial load could
affect fetal thymic development by comparing thymus weight of
pups (21-days-old) born to germ-free (GF) mice with those born
to specific pathogen free (SPF) mice. Thymic weight (Fig. 6a) and
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Fig. 4 Fetal thymus histopathology. Photomicrographs of fetal thymuses stained to compare CD4+ and Foxp3+ T-cell populations between the control
group and those mothers with preeclampsia at the time of fetal demise. a Fetal thymuses of Control (upper panel) and preeclamptic mothers (lower panel),
at 24 weeks gestation. b A 33-week-old control fetus (upper panel), versus a 37-week-old fetus deceased to a mother who had preeclampsia (lower panel).
Scale bars for H&E stains and CD4 stains= 100 µm. Scale bars for Foxp3 stains= 20 µm
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thymocyte cellularity (Fig. 6b) in GF mice was approximately half
that of SPF mice, which is similar to our findings in preeclampsia,
which we found to be associated with low acetate levels. Since our
human cohort showed that serum acetate levels were tenfold
higher compared to butyrate and propionate, we then supple-
mented the GF pregnant mice with acetate in the drinking water
and analyzed pups. Interestingly, maternal acetate supplementa-
tion rescued both thymic weight and thymocyte cellularity in
pups to levels comparable to SPF mice (Fig. 6a, b). This suggests
that maternal gut microbiota-derived acetate contributes to fetal
thymic development. Thymic progenitors are bone marrow-
derived and in addition to the lower thymic cellularity, GF mice
also had significantly reduced bone marrow cellularity (Fig. 6c);
in particular, lymphoid-primed multipotent progenitors
(CD62L+ LMPP; Fig. 6d), which supply the thymus with pro-
genitor cells for T-cell development. Maternal acetate supple-
mentation improved both bone marrow cellularity and CD62L+
LMPP cell proportions in pups (Fig. 6c, d), in parallel with thymic
cellularity normalization.
Maternal acetate potentiates fetal T-cell development. We then
compared the development of T-cell subsets in GF and SPF
fetuses. Offspring of GF mice had decreased total CD4+ T-cell
numbers (Fig. 6e) and fewer CD4+ Foxp3+ Tregs (Fig. 6f). In
addition, reduced abundance of Foxp3 protein per cell, measured
by mean fluorescence intensity (MFI), was apparent in GF mice
(Fig. 6g). Interestingly, maternal acetate supplementation restored
the total number of CD4+ T cells in pups to that of SPF mice.
While Treg numbers did not increase, acetate supplementation
rescued Foxp3 MFI in Treg cells (Fig. 6g), with implications in
Treg function. Altogether these results suggest that bacteria-
derived acetate is important for fetal CD4+ T-cell and Treg cell
development and dietary acetate supplementation can correct
defects resulting from an absent microbiota.
Maternal acetate recovers offspring thymic AIRE expression.
AIRE contributes to Treg cell generation early in life28 and Foxp3
levels are important for Treg function38, therefore we investigated
for alterations in AIRE expression in thymic epithelial cells. AIRE
is mostly expressed in thymic epithelial cells39. Our gating
strategy for flow cytometry was based on the expression of
europaeus agglutinin 1 (UEA1) lectin, which discriminates cor-
tical thymic epithelial cells (cTEC; UEA1-) from medullary epi-
thelial cells (mTEC; UEA1+) while both subsets express major
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histocompatibility complex II (MHC II) (Fig. 7a and Supple-
mentary Fig. 5a). The majority of AIRE+ cells are found in the
keratin 14+ medulla region (Supplementary Fig. 5b). However,
we also found a minority of AIRE+ cells with a cortical phenotype
(β5t+, keratin 14−) situated at the cortico-medullary junction
(white arrows, Supplementary Fig. 5b). We found a significant
reduction in the number and proportion of AIRE expressing cells
in the cTEC subset in GF mice while AIRE-positive cells among
the mTEC were unchanged (Fig. 7d, e), suggesting a differential
role for gut bacterial metabolites on AIRE expression in these
subsets. The proportion of AIRE expressing cTEC was normal-
ized in the offspring of mice supplemented with acetate during
pregnancy (Fig. 7b, c). Therefore, the impact of acetate on AIRE+
cTEC population might contribute to the effect of acetate on
Foxp3 expression in Tregs.
Discussion
These studies provide a plausible link between the maternal
intestinal bacterial metabolite acetate, thymus, and Treg cell
development in the context of preeclampsia, which is a pregnancy
disorder associated with important adverse outcomes for both the
mother and their offspring. We definitively demonstrated an
association between preeclampsia and fetal thymic hypoplasia.
Fetal thymus diameter at mid-gestation might have clinical utility
as a predictive tool for preeclampsia. This is illustrated by ROC
curve analysis, which returned an AUC of 0.81 for a model
consisting of fetal thymus diameter at mid-gestation, fetal head
circumference at mid-gestation, gestational age, and maternal
BMI. Such an early, non-invasive predictor of preeclampsia could
have significant clinical value; however, the utility of this index
would require further evaluation.
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Fig. 6 Reduced Foxp3 MFI in thymic Treg cells from GF pups recovered with acetate supplementation. Three-week-old C57BL/6 pups from control SPF and
GF mothers and GF mothers treated with acetate in drinking water (ADW). Cumulative data showing phenotypic analysis by flow cytometry in the thymus
from pooled female and male pups (n= 7–10/group). a Thymus weight. b Thymocyte cellularity per thymic lobe. c Bone marrow cellularity. d The
frequency of bone marrow CD62L+ lymphoid-primed multipotent progenitor (LMPP) cells. e The total number of CD4SP cells. f The total number of
CD4SP Foxp3+ cells. g Foxp3 protein expression on a per cell basis in thymic CD4SP Foxp3+ cells. Gating strategies for LMPP cells, CD4SP cells and
Foxp3+ cells are shown in Supplementary Figs. 3 and 4. The data are shown as mean fluorescence intensity (MFI). *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001. All data were analyzed by one-way ANOVA with Bonferroni’s multiple comparisons test. Data represent mean; each symbol represents an
individual mouse. Data are representative of at least two independent experiments
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Furthermore, we showed the impact of impaired fetal thymic
development with reduced Treg cell output in the offspring of
preeclamptic mothers, which was evident at birth and persisted
into early childhood. We then showed a reduction in Treg cell
frequency in preeclamptic mother-infant dyads compared to
healthy pregnancies, consistent with a deficit in an immune
regulatory factor that is able to cross the placenta. Further
examination of cord blood Treg cells revealed that the deficiency
mainly lies in the resting and thymus-derived Treg cells, impli-
cating reduced thymic Treg cell output, which is also consistent
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with absent Foxp3+ cells in thymic sections of deceased fetuses of
preeclamptic mothers. We found no evidence that preeclamptic
pregnancies were associated with changes in percentages of fetal
thymic T cells (CD3 T cells), or conventional CD4/CD8 T-cell
subsets (Supplementary Fig. 6). We have no data on the absolute
(total) numbers of thymic Treg cells or CD4/CD8 T-cell subsets.
To calculate total numbers of these subsets would have required
the availability of full blood counts, which were not systematically
collected for any of the cohorts. However, there is compelling
data suggesting that changes in percentages of Treg cells within
CD4+ cells play a central role in many immune-mediated
pathologies40–43. In line with this, our own group has shown
reduced percentages in maternal Tregs to be a feature of altered
immunity in preeclampsia4,44,45. Hence, differences in percen-
tages of offspring Treg cells described in this study between the
preeclampsia and non-preeclampsia groups seems highly rele-
vant. Importantly, we showed that fetal thymic changes precede
clinical preeclampsia suggesting that these deficits in fetal
immune development may be a component of the primary
pathology driving preeclampsia, rather than a consequence of
physiological stress associated with the clinically manifest disease.
Many factors may affect fetal immune development. Previously
we showed that IL-10 is likely to be involved in the fetal-maternal
alignment of Treg cells4. However, while IL-10 levels are reduced
in preeclampsia46, there is little to support its role in fetal thymic
development. By contrast, mounting evidence implicates the role
of microbial production of SCFAs in shaping both the innate
and adaptive immune system47. Interestingly, changes in the oral
and placental microbiota have been observed in preeclampsia48,49
and a high-fiber diet appears to be protective against the devel-
opment of preeclampsia19, consistent with a role for diet-
microbiota interplay in the prevention of preeclampsia. More-
over, the fact that acetate also has a direct effect on systemic blood
pressure20, implies beyond its immune modulating effects, a
special role of this SCFA in preeclampsia with hypertension as its
defining clinical feature20.
In view of this, we sought to test whether maternal gut
microbiota metabolites might influence fetal thymic immune
development. In a mouse model, we found a key role for maternal
microbiota on lymphoid organs and immune cell development.
We show that the maternal acetate can affect the development of
both thymus and bone marrow in the offspring as well as CD4+
T-cell development and the expression of AIRE and Foxp3, key
components for Treg function. The absence of a maternal gut
microbiota led to the offspring with reduced BM-derived LMPP
precursors that may underpin the substantial reduction in thymic
size and thymic output. This could be rescued by supplementing
maternal drinking water with acetate, which is the most abundant
SCFA in human serum12,50,51. Decreased Treg cell Foxp3 levels
were also found coincident with a reduction in AIRE expression
in specialized thymic epithelial cells in the absence of maternal
gut microbiota. Both were rescued with maternal acetate sup-
plementation. Treg cell generation is influenced by levels of AIRE
expression in medullary thymic epithelial cells52 and their func-
tional status is reflected by the levels of Foxp338. While the
majority of AIRE expression is found deep within the thymic
medulla, we identified a small proportion of AIRE expressing
mature cortical thymic epithelial cells located at the cortico-
medullary junction that was influenced by maternal gut micro-
biota. Our findings that a reduction in this specialized AIRE+
epithelial cell population is associated with the levels of Foxp3
expression in Treg cells, suggests a role in Treg functionality.
While AIRE expressing medullary epithelial cells express specia-
lized tissue-restricted self-antigens, these cortical epithelial cells
may present abundant, ubiquitous self-antigens early in Treg
development53. Thus, recovery of AIRE expression in cortical
epithelial cells and increased Foxp3 expression levels with
maternal acetate supplementation suggests that maternally
derived acetate may influence Treg cell functional development in
offspring. However, the exact mechanisms by which acetate
enhances AIRE and Foxp3 expression and how they may be
related, require further investigations. Collectively, these data
suggest that maternally derived acetate plays important roles in
shaping fetal thymic development and output. This is also con-
sistent with the maternal-fetal correlation for serum acetate levels
we found in human pregnancy, suggesting that maternal acetate
likely crosses the placenta and influences fetal immunity as pre-
viously seen in a mouse model of asthma15.
In support of our hypothesis, we found evidence of an asso-
ciation between low serum acetate and subsequent preeclampsia
in a pregnancy cohort. Acetate levels fluctuate depending on
recent dietary intake and microbial composition50,51. Therefore, a
single measurement of serum acetate levels can only provide a
snapshot and not the cumulative exposure to acetate over the
duration of pregnancy. Further longitudinal studies, with larger
numbers of women with preeclampsia, are required to assess
acetate production in the context of microbiota composition and
diet throughout preeclampsia and healthy pregnancy.
Importantly we found that the fetal immune consequences of
preeclampsia are persistent, with reduced Treg frequency
observed beyond infancy and into early childhood. This suggests
that preeclampsia has long term implications for immune func-
tion in offspring. While the precise mechanisms underlying
impaired fetal thymus development in preeclampsia remain
uncertain, we suggest a key influence of maternal microbiota on
this process, possibly through a direct effect of SCFAs on the fetal
bone marrow and thymus.
In conclusion, this research extends our understanding of the
human maternal-fetal interaction in preeclampsia and adds an
alternative dimension to our conception of the developmental
origins of health and disease. In addition to maternal morbidity,
fetal thymic development, and Treg output are adversely affec-
ted in preeclamptic pregnancies. These associated immune
changes persist into early childhood, which might explain the
association between preeclampsia and later allergy in
offspring5,6, though further investigations in longitudinal cohort
studies are required. Additionally, whether fetal thymic hypo-
plasia is mediated via dysbiosis and consequent alterations in
bacterial metabolites in humans needs to be further investigated.
The answers to these questions may help to establish future
primary prevention strategies for preeclampsia and adverse fetal
immune outcomes.
Methods
Human cohorts. Nepean cohort 1: Prospective, case–control, comparative study:
preeclamptic (n= 50) and healthy pregnant (n= 50) women were recruited.
Written consent was obtained from all participants prior to entry. Preeclamptic
patients were identified by daily monitoring of the antenatal ward, labor ward, and
clinic attendance. Participants in the preeclampsia group underwent an ultrasound
examination at Nepean Hospital (NSW, Australia) within 48 h of diagnosis.
Control participants were women who presented to Nepean Hospital for a routine
pregnancy ultrasound examination. Participants were recruited consecutively,
subject to eligibility. Participants were eligible if they had a singleton pregnancy of
gestational age ≥ 20 weeks, a normal morphology scan between 18–20 weeks and
were aged between 18–40 years with no pre-existing medical conditions. Partici-
pants were excluded on the basis of chronic hypertension, illicit drug use or alcohol
consumption, or obstetric complications during pregnancy (excluding pre-
eclampsia in the preeclampsia group), or a history of intellectual or mental
impairment. The Ethics Committee of the Sydney West Area Health Service,
Australia approved this project (Study12/23—HREC/12/NEPEAN/45).
Nepean cohort 2: Prospective, (n= 887), of this group 24 developed
preeclampsia. Pregnant women carrying a single fetus were recruited between 15
January 2011 and 15 July 2013, at the time of their mid-gestation ultrasound scan
(17–22 weeks). In all instances, a participant information sheet was provided, and
written consent was obtained by sonographers within the Perinatal Ultrasound
Unit at Nepean Hospital. During the data collection period, 1155 pregnant women
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were consented to participate. Fetal thymus diameter measurements were
performed by one of the authors (D.P.E.) from 1139 mid-gestation scans, with an
image of the right ventricular outflow tract (RVOT) unavailable in 16 scans. Once
all measurements had been performed and allowing sufficient time for the last
participating woman to be delivered, the ObstetriX database was searched for
preeclampsia diagnoses, plus other maternal and child variables. ObstetriX is
updated during and after pregnancy, by medical officers and midwives, and
contributes to State-wide data collection. In total, 950 consented pregnancies were
delivered at Nepean Hospital. Fifty pregnancies were excluded, based on another
hypertensive diagnosis (gestational hypertension= 34, essential hypertension=
16). A further 13 pregnancies were excluded because their ultrasound scan was
performed outside the range of 17–22 weeks. Participating women were not
represented in more than one pregnancy. The Ethics Committee of the Sydney
West Area Health Service, Australia approved this project (Study 10/14—HREC/
10/NEPEAN/33).
Nepean cohort 3: Peripheral blood samples were obtained from healthy (n= 66)
or preeclamptic pregnant (n= 30) patients. Formal consent was obtained from all
patients. Preeclampsia was defined as per International Society for the Study of
Hypertension in Pregnancy (ISSHP) criteria as onset of high blood pressure (>140/
90) and proteinuria (>0.3 g/24 h) after 20 weeks of gestation54. None of the patients
had HELLP syndrome or eclampsia. Exclusion criteria included gestational
diabetes, infectious conditions, multiple births and chromosomal abnormalities.
The Ethics Committee of the Sydney West Area Health Service, Australia approved
this project (HREC 05/041).
Nepean cohort 4: Serum samples of paired maternal and fetal blood, collected no
longer than 4 h apart, were extracted from blood samples and then stored at -80°
until further analyses. Formal consent was obtained from all patients. Selection
criteria were the same as in Nepean cohort 3. The Ethics Committee of the Sydney
West Area Health Service, Australia approved this project (HREC 05/041).
BIS cohort: The aims and methodology of the Barwon Infant Study (BIS) have
been previously described55. In brief, The Barwon Infant Study (BIS) is an
Australian birth cohort study (n= 1064 mothers/1074 infants) recruited prior to
32 weeks of gestation. Exclusion criteria included birth before 32 weeks of
gestation, major congenital malformation and/or genetically determined disease.
Preeclampsia was defined as above. Participants with preeclampsia (n= 31) were
compared to a randomly selected sub cohort of 293 participants without
preeclampsia. All participants had provided informed consent. The study was
approved by the Barwon Health Human Research and Ethics Committee (HREC
10/24).
Fetal autopsy cohort: Two cohorts of patients were recruited: one was from
Westmead Children’s Hospital (Sydney, Australia), and the other was from the
Canberra Hospital (Canberra, Australia). The tissue sample were archived after
biopsy, and all families of the deceased had consented to the retention of the tissues
as part of the autopsy assessment. Since tissue samples belonged to Category S3
under Human Research and Ethics Committee Guidelines, which are considered as
low risk, the ethics committee had approved the use of tissue samples and advised
that no additional consent was required (ACT Health, Human Research and Ethics
Committee, ethlr.12.182). Overall, five fetuses born to preeclamptic women in the
second or third trimester of pregnancy and six age-matched controls were studied.
The control patients had no clinical or biochemical evidence of preeclampsia.
Mothers with other pregnancy-related complications, such as gestational diabetes
or underlying autoimmune problems, were excluded from the study. Fetuses with
congenital abnormalities known to affect the thymic development (e.g., 22q11
deletion) or known to be associated with any effect on T-cell populations were
excluded. All cases selected histologically showed only minimal autolysis of the
tissues and had their post-mortems performed close to the time of delivery.
Sequential cases were selected that met the inclusion criteria. Demographics from
both cohorts including gestational age, mother’s age, mother’s parity, the cause of
fetal death, duration of preeclampsia, highest BP recorded, drug management of
the blood pressure, the weight of the fetus, the weight of the thymus and spleen and
placental weight and findings are summarized in Supplementary Table 5a. No
information was available in relation to maternal diet or maternal or fetal serum
acetate levels.
Fetal thymus volume measurement. Fetal thymus volume for Nepean cohort 1
was obtained by three-dimensional ultrasound (3D-US) using a 45-degree sweep
angle when a two-dimensional ultrasound (2D-US) image showed clear thymic
borders. Once 3D-US image data was acquired, the information was digitally stored
and later analyzed by virtual organ computer-aided analysis (VOCAL) in View-
point software, version 5.6.12.601 (ViewPoint Bildverarbeitung GmbH, a GE
Healthcare subsidiary). Transverse, coronal, and sagittal planes were displayed by
VOCAL. The transverse plane was identified and rotated in 30-degree increments
for 180 degrees and the borders were manually drawn throughout the rotation. In
this way, VOCAL identified the thymic borders in coronal and sagittal planes and
automatically calculated the volume (Fig. 1a). Where high-quality images of the
thymus could not be obtained, repeat examinations were performed. Each para-
meter was measured three times, with the mean of each parameter used in data
analysis.
Intra-observer reliability was performed by the same examiner (S.J.) at a later
date from 30 randomly selected images. To assess inter-rater reliability, 30 fetal
thymus measurements were randomly selected and repeated by an independent
examiner (A.E.Q.).
Fetal thymus diameter measurement. Fetal thymus diameter for Nepean cohort 2
was measured using 2D-US (Voluson 730 and E8; GE Healthcare, Zipf, Austria),
with a transverse view of the fetal thymus obtained and stored using ViewPoint
software, version 5.6.12.601 (ViewPoint Bildverarbeitung GmbH, a GE Healthcare
subsidiary). The fetal thymus was visualized in the anterior mediastinum, within a
saved image of the right ventricular outflow tract (RVOT). Fetal thymus diameter
was measured as its greatest width perpendicular to a line connecting the sternum
and spine (Fig. 1c).
To test the intra-observer reliability of fetal thymus diameter measures, 40
repeated measures were performed by D.P.E. several weeks after the primary
measurements. Inter-rater reliability was assessed by comparing 40 primary
measurements with those made by a second rater (A.E.Q.). Pregnancies were
randomly selected in both instances. A good degree of correlation was observed for
repeated thymus diameter measures in both intra-observer reliability (Pearson r=
0.87, p < 0.001) and inter-rater reliability (Pearson r= 0.72, p < 0.001) analyses. In
addition, intra-observer and inter-rater reliability showed good correlation in both
thymus diameter and volumes, with Lins concordance coefficients of 0.96 and 0.99,
respectively.
Mononuclear cell isolation. Mononuclear cells from the Nepean Cohorts were
isolated using Ficoll-Hypaque (Amersham Pharmacia, Piscataway NJ) density
gradient centrifugation. All samples were frozen at −196 °C for further flow
cytometric analysis. Human serum samples were obtained after centrifugation at
1000 × g for 10 min, aliquoted and stored at −80 °C.
BIS cohort: Umbilical cord blood was collected by syringe and immediately
diluted in 10 IU/mL preservative-free sodium heparin (Pfizer) in 10 mL of RPMI
1640 (Gibco, Life Technologies). Venous peripheral blood (PB) was collected at
6 months, 1 year, and 4 years of age and added to a 15 mL tube containing 10 IU/
mL preservative-free sodium heparin (Pfizer). All blood was processed within 18 h
of collection. Mononuclear cells were isolated by density gradient centrifugation
(Lymphoprep, Axis-Shield), and flow cytometry performed in infants from
preeclamptic mothers (cord blood, n= 11; 6-month PB, n= 19; 1-year-old PB,
n= 22; 4-year-old PB, n= 10) and infants from non-hypertensive mothers
(cord blood, n= 434; 6-month PB, n= 558; 1-year-old PB, n= 629; 4-year-old PB,
n= 377).
Flow cytometry. Nepean cohort 3: Mononuclear cells were first stained using
surface antibodies, after fixation and permeabilization with the Foxp3 Fix/Perm
Buffer Set intracellular staining for Foxp3 was performed according to the man-
ufacturer’s instructions. Data collection was performed on a FACSVerse (BD) and
data files analyzed using FlowJo software V9 (Treestar, San Carlos, CA).
BIS cohort: To measure Treg subsets cells were stained with antibodies to
surface antibodies, and formalin fixed. After overnight fixation, cells were
permeabilized (0.5% Tween) and stained with anti-Foxp3. Samples were analyzed
either by the FACSCalibur (3-channel, BD) or FACSCanto II (8-channel, BD) and
analyzed on complementary software. Antibodies used for flow cytometric staining
of samples of the Nepean cohort 3 include: V500 anti-CD4 (BD, 562970, 1:40),
APC-H7 anti-CD3 (BD, 560176, dilution 1:40), AF488 anti-Foxp3 (BioLegend,
320212, 1:50), and V450-anti-Helios (Biolegend, 137220, 1.5:100). Antibodies used
for the BIS Cohort include: AF488-anti Foxp3 (BD, 560047, 1:20), PE-anti-CD4
(BD, 550630, 1:20), and PE-Cy5.5-anti-CD45RA (BD, 555490, 1:20). For both
cohorts, isotype controls were used to set up the instrument for positive gating,
and, once established, these settings were maintained throughout.
Serum acetate measurement. Maternal serum samples collected at 28 weeks of
pregnancy were transported at −80 °C to the CSIRO (Commonwealth Scientific
and Industrial Research Organization) laboratories, Adelaide, Australia, where
serum acetate was quantified by capillary gas chromatography (GC; 5890 series II
Hewlett Packard, Australia)56. The researchers were blinded to the
experimental group.
Nuclear magnetic resonance (NMR) spectroscopy. Samples stored at −80 °C
were thawed and 110 µL of serum transferred to a fresh 1.5 mL Eppendorf tube,
and 450 µL of 1 x DPBS (Gibco Life Technologies), 50 µL of D2O (Cambridge
Isotope Laboratories, Inc, MA, USA), and 10 µL of sodium 2,2-dimethyl-2-sila-
pentane-5-sulfonate (DSS) (Cambridge Isotope Laboratories, Inc, MA, USA)
(3.7 mg in 700 µL MilliQ water) added. Samples were centrifuged at 14,000 rpm for
10 min at 4 °C, and 550 µL transferred to an NMR tube. One-dimensional NMR
spectra (128 scans) were recorded at 298 K using a standard CPMG sequence on a
Bruker Avance III 600MHz spectrometer equipped with a cryoprobe using auto-
mated data collection via IconNMR software (Bruker). Two-dimensional spectra
were recorded on selected samples, including COSY, TOCSY, and 1H-13C-HSQC.
Samples were processed randomly. Metabolite assignments were based on the
Human Metabolome Database57 and chemical shifts derived from standard sam-
ples. For the statistical analysis, spectra were normalized to total intensity.
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Immunohistochemistry. The spleen and thymus from the fetuses had been for-
malin fixed and processed into paraffin blocks using routine laboratory methods.
Sequential IHC staining was performed to access the presence, location, and
intensity of CD4 and Foxp3 expression of lymphocytes using the Leica Bond fully
automated system (Vision Biosystems, Mt. Waverley, Australia), following a
standard protocol. The cases were deidentified at time of sectioning.
Briefly, tissue sections were cut (4 µm thick) and dried in an oven at 60 °C for
1 h. Foxp3 (ab20034; Abcam, Cambridge, UK), 1:200 dilution was incubated for
15 min following 20 min heart retrieval using Bond Epitope Retrieval Solution
(BERS) 2 from Leica Microsystems (Sydney, Australia), pH 8.9 to 9.1. The
detection kit used was the Leica Bond Polymer Refine Detection Kit (a polymeric
HRP-linker antibody conjugate system, Sydney, Australia). The same protocol was
used for CD4 (NCL-L CD4–368, Novocastra 1/50 dilution). The sections were
counterstained with hematoxylin to allow visualization of the nuclei, coverslipped,
and viewed.
The number of CD4+ and Foxp3+ cells was counted across ten high-power
fields (original magnification, x40) and scored as 0= 0% of cells, 1= <10%, 2=
10–75%, 3= >75%. The intensity of the stain was recorded as weak (1), moderate
(2), or strong (3). This was performed on two separate occasions and the mean
score used. The external positive control for the antibodies was an adult tonsil.
Negative internal control were endothelial cells and also the omission of the
primary antibody. The location of the T cells was recorded as medulla only, mainly
cortex, mainly medulla and cortex only. The pathologist (J.D.) was blinded to the
patient cohort at the time of assessment of the immunoreactivity of the sections. All
cases were photographed and sent to a second researcher for review.
Mouse experiments. Germ-Free (GF) C57BL/6 mice were derived from Germ-
Free Unit (Walter and Eliza Hall Institute of Medical Research). Pregnant GF mice
from E18 were fed ad libitum with sodium acetate (200 mM, except where indi-
cated) provided in the drinking water. Then 3-week-old pups (total, n= 10) were
studied for thymic analysis. Mouse thymic analyses were performed from two or
three separated cohorts of pups to obtain reproducibility. All experimental pro-
cedures involving mice had complied with all relevant ethical regulations for
animal testing and research, and carried out according to protocols approved by
the relevant Animal Ethics Committee of Monash University, Melbourne,
Australia.
Mouse thymuses were isolated and processed for T-cell analysis or thymic
epithelial cell analysis58. CD4+ T cells were stained using anti-mouse CD4 (Clone:
RM4–5, Pacific Blue, BD Biosciences, 558107, 1:400 dilution), anti-mouse CD25
(Clone: PC61, PE Cy7, 552880, BD Biosciences, 1:400 dilution) and anti-mouse
Foxp3 (Clone: FJK-16s, FITC, eBioscience, 11–5773–82, 1:200 dilution). The
following antibodies for thymic epithelial cell analysis by flow cytometry or
immunofluorescence studies were used: CD45 (30-F11, 1:400, BD Biosciences
557659), CD326/EpCAM (G8.8, 1:3000, eBioscience 25–5791–80), UEA-1 lectin
(1:4000, Vector Labs B-1065), MHC Class II (1:5000, Biolegend 107620), Ly51
(1:2000, BD Biosciences 553735)), and AIRE (5G12, 1:100, eBioscience
3–5934–82), β5t (1:400, MBL PD021), and Keratin 14 (1:400, Biolegend 906004).
For intracellular staining, cells were fixed using the Foxp3/Transcription Factor
Staining Buffer Kit (eBiosciences) according to the manufacturer’s instructions.
The stained mouse samples were analyzed using BD LSRII flow cytometers with
FACSDiva software (BD Biosciences) and FlowJo software version 9.3.2 (Tomy
Digital Biology).
Statistics. For comparisons among two or more groups, unpaired t-test or one-
way ANOVA with different types of corrections were performed for parametric
data; whereas Mann–Whitney test or Kruskal–Wallis test with Dunn’s correction
were used for nonparametric data. Chi-square tests were used to compare groups
on categorical variables. To test for correlations, Pearson’s correlations coefficient
was performed. All statistical analyses were performed using GraphPad Prism7 for
Windows (GraphPad Prism, San Diego, CA), SAS v9.3 (SAS Institute Inc., Cary,
NC, USA) or Stata 15.1 (StataCorp, College Station, TX, USA). For all analyses, a
p-value of <0.05 was considered statistically significant. Apart from the above-
mentioned statistical analyses, special analyses for each cohort are listed in detail as
follows:
For Nepean cohort 1, an initial power calculation revealed a sample of
100 subjects (50 cases with preeclampsia and 50 controls) to provide over 80%
power to detect an effect size of 0.6 on thymus volume at the 5% level of
significance. An effect of this magnitude represented a conservative interpretation
of the results of our previous study30, which found a difference in thymus diameter
corresponding to an effect size of 0.8 and obtained similar results using an
approximated thymus volume based on the diameter measures. Intra-observer and
inter-rater reliability were assessed used a Bland-Altman plot and a paired t-test for
each assessment. In addition, the Lins Concordance Correlation coefficient was
calculated to demonstrate reproducibility59.
For Nepean cohort 2, a power calculation predicted a study of n= 800 would
have at least 80% power at the two-sided 5% level of statistical significance to
identify, using logistic regression modeling, an odds ratio of 0.8 for preeclampsia
for every 1 mm increase in thymus diameter, given a standard deviation in
thymus measurements of 2.7 mm, and assuming the underlying prevalence
of preeclampsia is 2.8%. The sample calculation was performed using the
Shieh-Brien method implemented in SAS v9.2 and confirmed via simulation60.
The estimated prevalence of preeclampsia at Nepean Hospital was based on our
earlier retrospective study. The estimates of the standard deviation in thymus
diameter measurements and the plausible odds ratio are also informed by the
results of our previous retrospective study30. The effect of fetal thymus diameter
on the odds of preeclampsia was evaluated in both univariate and multivariate
logistic regression analyses (Model 1 and Model 2). Model 1 examined the
relationship between fetal thymus diameter and preeclampsia, adjusted for
gestation and maternal Body mass index (BMI). Multivariate Model 2 was
similar, except adjustment was made for fetal head circumference and maternal
BMI. The association between thymus diameter and gestational age was modeled
using multiple linear regression methods with preeclampsia status included as an
explanatory factor.
For BIS cohort: In examining the relationship between maternal serum acetate
and subsequent preeclampsia, potential confounding variables were determined
from a causal model represented by a directed acyclic graph (Supplementary
Fig. 7). Testable implications were checked in R using code generated by Dagitty.
Risk ratios for preeclampsia were calculated using binomial regression with a
logarithmic link function, with inverse sampling probability weighting to account
for the case-cohort design. Mediation was assessed using the Stata procedure
“medeff”. To examine potential sustained differences in nTreg proportions (birth, 6
and 12 months, and 4 years), a generalized estimating equation (GEE) regression
model for longitudinal measures was used.
For the Fetal autopsy cohort, fetal thymic and splenic expression of CD4+ and
Foxp3+ were compared between groups using an exact interpretation of the
Cochrane Armitage test for trend (SAS v9.3; SAS Institute Inc., Cary, NC, USA).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All data generated or analyzed during this study are included in this published article
(and its supplementary information files) or from the corresponding author upon
reasonable request. The source data underlying Figs. 1b, 1d, 2b, 2d, 3, 5a–e, 6a–g and 7d,
e are provided as a Source Data file.
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